These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

159 related articles for article (PubMed ID: 19761073)

  • 1. Seeking drug treatment for OxyContin abuse: a chart review of consecutive admissions to a substance abuse treatment facility in Kentucky.
    Hays L; Kirsh KL; Passik SD
    J Natl Compr Canc Netw; 2003 Jul; 1(3):423-8. PubMed ID: 19761073
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A profile of OxyContin addiction.
    Hays LR
    J Addict Dis; 2004; 23(4):1-9. PubMed ID: 15339710
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Trends in abuse of Oxycontin and other opioid analgesics in the United States: 2002-2004.
    Cicero TJ; Inciardi JA; Muñoz A
    J Pain; 2005 Oct; 6(10):662-72. PubMed ID: 16202959
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Abuse of reformulated OxyContin: Updated findings from a sentinel surveillance sample of individuals assessed for substance use disorder.
    Cassidy TA; Thorley E; Black RA; DeVeaugh-Geiss A; Butler SF; Coplan P
    J Opioid Manag; 2017; 13(6):425-440. PubMed ID: 29308589
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Abuse-Deterrent Formulations and the Prescription Opioid Abuse Epidemic in the United States: Lessons Learned From OxyContin.
    Cicero TJ; Ellis MS
    JAMA Psychiatry; 2015 May; 72(5):424-30. PubMed ID: 25760692
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prescription OxyContin abuse among patients entering addiction treatment.
    Carise D; Dugosh KL; McLellan AT; Camilleri A; Woody GE; Lynch KG
    Am J Psychiatry; 2007 Nov; 164(11):1750-6. PubMed ID: 17974941
    [TBL] [Abstract][Full Text] [Related]  

  • 7. OxyContin use and misuse in three populations: substance abuse patients, pain patients, and criminal justice participants.
    Wunsch MJ; Cropsey KL; Campbell ED; Knisely JS
    J Opioid Manag; 2008; 4(2):73-9. PubMed ID: 18557163
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Changes in drug use patterns reported on the web after the introduction of ADF OxyContin: findings from the Researched Abuse, Diversion, and Addiction-Related Surveillance (RADARS) System Web Monitoring Program.
    Vosburg SK; Haynes C; Besharat A; Green JL
    Pharmacoepidemiol Drug Saf; 2017 Sep; 26(9):1044-1052. PubMed ID: 28653782
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Incidence of nonmedical use of OxyContin and other prescription opioid pain relievers before and after the introduction of OxyContin with abuse deterrent properties.
    Cheng HG; Coplan PM
    Postgrad Med; 2018 Aug; 130(6):568-574. PubMed ID: 29978755
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prescription opioid dependence and treatment with methadone in pregnancy.
    Sander SC; Hays LR
    J Opioid Manag; 2005; 1(2):91-7. PubMed ID: 17319253
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A tale of 2 ADFs: differences in the effectiveness of abuse-deterrent formulations of oxymorphone and oxycodone extended-release drugs.
    Cicero TJ; Ellis MS; Kasper ZA
    Pain; 2016 Jun; 157(6):1232-1238. PubMed ID: 27186712
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Impact of abuse-deterrent OxyContin on prescription opioid utilization.
    Hwang CS; Chang HY; Alexander GC
    Pharmacoepidemiol Drug Saf; 2015 Feb; 24(2):197-204. PubMed ID: 25393216
    [TBL] [Abstract][Full Text] [Related]  

  • 13. OxyContin abuse and overdose.
    Aquina CT; Marques-Baptista A; Bridgeman P; Merlin MA
    Postgrad Med; 2009 Mar; 121(2):163-7. PubMed ID: 19332974
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Evaluating the potential impact of a reformulated version of oxycodone upon tampering, non-adherence and diversion of opioids: the National Opioid Medications Abuse Deterrence (NOMAD) study protocol.
    Degenhardt L; Larance B; Bruno R; Lintzeris N; Ali R; Farrell M
    Addiction; 2015 Feb; 110(2):226-37. PubMed ID: 25358480
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Sustained reduction of diversion and abuse after introduction of an abuse deterrent formulation of extended release oxycodone.
    Severtson SG; Ellis MS; Kurtz SP; Rosenblum A; Cicero TJ; Parrino MW; Gilbert MK; Buttram ME; Dasgupta N; BucherBartelson B; Green JL; Dart RC
    Drug Alcohol Depend; 2016 Nov; 168():219-229. PubMed ID: 27716575
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The development of a comprehensive risk-management program for prescription opioid analgesics: researched abuse, diversion and addiction-related surveillance (RADARS).
    Cicero TJ; Dart RC; Inciardi JA; Woody GE; Schnoll S; Muñoz A
    Pain Med; 2007 Mar; 8(2):157-70. PubMed ID: 17305687
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Monitoring of internet forums to evaluate reactions to the introduction of reformulated OxyContin to deter abuse.
    McNaughton EC; Coplan PM; Black RA; Weber SE; Chilcoat HD; Butler SF
    J Med Internet Res; 2014 May; 16(5):e119. PubMed ID: 24800858
    [TBL] [Abstract][Full Text] [Related]  

  • 18. An exploratory study of OxyContin use among individuals with substance use disorders.
    Levy MS
    J Psychoactive Drugs; 2007 Sep; 39(3):271-6. PubMed ID: 18159780
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Estimating attractiveness for abuse of a not-yet-marketed "abuse-deterrent" prescription opioid formulation.
    Butler SF; Black R; Grimes Serrano JM; Folensbee L; Chang A; Katz N
    Pain Med; 2010 Jan; 11(1):81-91. PubMed ID: 20002324
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Non-medical use of OxyContin Tablets in the United States.
    Sees KL; Di Marino ME; Ruediger NK; Sweeney CT; Shiffman S
    J Pain Palliat Care Pharmacother; 2005; 19(2):13-23. PubMed ID: 16061457
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.